In an 83‑year‑old woman with panic disorder (ICD‑10 F41.0) taking sertraline 150 mg daily, mirtazapine 30 mg at night, propranolol 40 mg as needed, and several cardiovascular and bone‑health medications, who has persistent panic symptoms, insomnia, and weight loss and wishes to stop sertraline, what alternative antidepressant or anxiolytic options are appropriate and is the orexin antagonist daridorexant suitable for her insomnia?

Management Plan for 83-Year-Old Woman with Panic Disorder

Direct Answer to Medication Switch Question

For this 83-year-old woman wishing to discontinue sertraline, venlafaxine 75-150 mg daily represents the strongest evidence-based alternative antidepressant for panic disorder, while daridorexant 50 mg is an appropriate and well-tolerated option specifically for her insomnia. 1, 2, 3

---

Rationale for Switching from Sertraline

Why Consider a Switch

• Patient reports sertraline was "taken away" when amitriptyline (which provided good sleep) was stopped due to perceived interaction concerns 4
• Current regimen shows suboptimal response: persistent panic symptoms, severe insomnia (4 hours sleep, waking after 2am), weight loss, and ongoing distress despite maximum-dose sertraline (150 mg) 4
• Sertraline carries serotonin syndrome risk when combined with mirtazapine, though this combination is commonly used; the patient's concern about drug interactions is valid and affects adherence 4

---

Alternative Antidepressant Options

First Choice: Venlafaxine (SNRI)

Venlafaxine 75-150 mg daily is the recommended alternative, based on:

• Strongest efficacy evidence in panic disorder among alternatives, ranking highest alongside paroxetine and clomipramine in network meta-analysis 2, 3
• Effective for panic with comorbid anxiety and insomnia 5
• No significant difference in dropout rates versus sertraline, suggesting comparable tolerability 5
• Start at 37.5 mg daily and titrate up by 37.5-75 mg weekly to minimize initial anxiety exacerbation 6

Second Choice: Paroxetine (SSRI)

• If staying within SSRI class is preferred, paroxetine 20-40 mg daily shows stronger panic disorder efficacy than sertraline 2, 3
• Ranked higher than sertraline in multiple meta-analyses for panic symptom reduction 2, 3
• Caution: More anticholinergic effects and withdrawal symptoms than sertraline; requires very gradual taper when discontinuing 6

Mirtazapine Optimization

Continue mirtazapine 30 mg at night because:

• Mirtazapine monotherapy shows efficacy for panic disorder comparable to fluoxetine, with faster onset of action (within 2 weeks) 7, 8
• Already on therapeutic dose (15-30 mg range effective) 7, 8
• Provides sedation and appetite stimulation, addressing her insomnia and weight loss 9, 7
• Network meta-analysis supports mirtazapine for overall anxiety symptoms in panic disorder 2

---

Addressing Insomnia: Daridorexant

Is Daridorexant Appropriate?

Yes, daridorexant 50 mg is highly appropriate for this patient based on:

Efficacy in Older Adults

• Phase III trial specifically in adults ≥65 years (n=364) demonstrated daridorexant 50 mg reduced wake after sleep onset by 19.6 minutes and increased total sleep time by 59.9 minutes at 3 months 1
• Improved daytime functioning measured by IDSIQ scores, with effects maintained through 12 months of treatment 1, 10
• No dose reduction needed for age - older adults require the full 50 mg dose to achieve optimal daytime functioning benefits 1

Safety Profile in Elderly

• No increased adverse events in older adults compared to younger patients 1
• Reduced fall risk compared to placebo in both age groups - critical for 83-year-old with osteoporosis on risedronate 1
• No next-morning residual sleepiness on Visual Analog Scale measurements 1, 10
• No withdrawal symptoms or rebound insomnia after discontinuation in 40-week extension study 10
• No cases of complex sleep behaviors, cataplexy, or narcolepsy in older adults 11, 1

Advantages Over Alternatives

• American Academy of Sleep Medicine guidelines suggest orexin antagonists (suvorexant) for sleep maintenance insomnia, but evidence for daridorexant is more recent 12
• Safer than benzodiazepines in elderly (no cognitive impairment, falls, or dependence) 12, 1
• More effective than trazodone, which AASM guidelines recommend against 12
• Low-dose doxepin 3-6 mg is an alternative AASM-recommended option for sleep maintenance, but daridorexant has superior elderly-specific data 12, 1

Drug Interactions

• Minimal interaction concerns with her current medications 11
• Can be used with SSRIs/SNRIs and mirtazapine without serotonin syndrome risk 11
• Caution with moderate hepatic impairment - she has no documented liver disease, but monitor LFTs given multiple medications 11

---

Propranolol Optimization

Current Use: 40 mg TDS PRN

Recent 2025 evidence supports continuing propranolol alongside antidepressant:

• Sertraline plus propranolol significantly superior to sertraline plus placebo for panic attack severity (mean score 6.6 vs 13.1, p<0.001) and depression scores (8.9 vs 15.5, p=0.001) in women with panic disorder 13
• Consider scheduled dosing rather than PRN: propranolol 20-40 mg three times daily may provide more consistent benefit 13
• Monitor for bradycardia and hypotension given concurrent ramipril and amlodipine 13

---

Switching Strategy: Sertraline to Venlafaxine

Cross-Taper Protocol

1. Week 1-2: Start venlafaxine XR 37.5 mg daily while continuing sertraline 150 mg 6
2. Week 3: Increase venlafaxine to 75 mg; reduce sertraline to 100 mg 6
3. Week 4: Maintain venlafaxine 75 mg; reduce sertraline to 50 mg 6
4. Week 5: Increase venlafaxine to 150 mg; discontinue sertraline 6
5. Consider short-term lorazepam 0.5-1 mg twice daily during weeks 1-4 to manage transition anxiety, then taper 6

Monitoring During Switch

• Weekly contact first month to address anxiety symptoms misattributed to medication side effects 6
• Educate about potential initial anxiety increase with venlafaxine - this is temporary and improves by week 2-4 6
• Monitor blood pressure given venlafaxine can increase BP, especially with concurrent antihypertensives 5

---

Addressing Weight Loss and Appetite

Contributory Factors

• Anxiety-related appetite suppression [@patient history@]
• Sertraline can cause weight loss in some patients 4
• Mirtazapine typically increases appetite but may need optimization 9

Management

• Mirtazapine 30 mg is appropriate dose for appetite stimulation 9, 7
• Venlafaxine is weight-neutral to slight weight loss - monitor closely 5
• Consider nutritional supplementation and small frequent meals [@clinical practice@]
• Rule out occult malignancy or GI pathology given age and unexplained weight loss [@clinical practice@]

---

Sleep Hygiene Optimization

Current Pattern Issues

• "Goes to bed as late as possible to take tablet late" - maladaptive behavior perpetuating insomnia [@patient history@]
• Wakes after 2am, cannot return to sleep - classic sleep maintenance insomnia [@patient history@]

Specific Recommendations

• Fixed bedtime of 10-11 PM regardless of sleepiness [@clinical practice@]
• Take mirtazapine 30 mg at 9 PM (1 hour before bed) 9
• Take daridorexant 50 mg immediately before bed (within 30 minutes of lights out) 11
• Limit alcohol - her "occasional half vodka" disrupts sleep architecture [@clinical practice@]
• Avoid news watching before bed - she reports watching news since age 18, likely contributing to anxiety [@patient history@]

---

Monitoring "Crawly Little Things" Head Sensation

Differential Diagnosis

• Formication (tactile hallucination) - can occur with severe anxiety or as medication side effect [@clinical practice@]
• Paresthesias from sertraline - resolves with discontinuation 4
• MRI already performed ruling out structural lesions [@patient history@]

Management

• Likely anxiety-related and should improve with optimized panic treatment [@clinical practice@]
• Monitor after sertraline discontinuation - may be medication-related 4
• Reassure patient - not indicative of dementia given normal cognition and recent normal MRI [@patient history@]

---

Addressing Dementia Fears

Reassurance Based on Assessment

• Fully oriented to time, place, person [@patient history@]
• Recent normal MRI [@patient history@]
• Anxiety-related cognitive complaints (pseudodementia) common in panic disorder [@clinical practice@]
• Insomnia significantly impairs cognition - expect improvement with sleep treatment 1

Ongoing Monitoring

• Repeat cognitive screening in 6 months if concerns persist after anxiety/sleep optimization [@clinical practice@]
• Daridorexant does not impair cognition and may improve daytime cognitive function through better sleep 1, 10

---

Cardiovascular Medication Interactions

Current Medications Review

• Ramipril 5 mg, amlodipine 10 mg, atorvastatin 20 mg - no significant interactions with venlafaxine, mirtazapine, or daridorexant 11
• Propranolol with ramipril/amlodipine - additive hypotensive effects, monitor BP and adjust if needed [@clinical practice@]
• Lansoprazole - no interactions with psychiatric medications [@clinical practice@]

---

Summary of Recommended Changes

Immediate Actions

1. Initiate daridorexant 50 mg nightly for insomnia 11, 1
2. Continue mirtazapine 30 mg at 9 PM 9, 7
3. Begin cross-taper from sertraline 150 mg to venlafaxine XR using protocol above 6, 2
4. Consider scheduled propranolol 40 mg TDS (not PRN) based on 2025 evidence 13
5. Weekly follow-up first month, then biweekly for 3 months 6

Expected Timeline

• Sleep improvement: 1-2 weeks with daridorexant 1
• Panic symptom reduction: 4-6 weeks with venlafaxine 2
• Daytime functioning improvement: 2-4 weeks 1
• Full response assessment: 12 weeks 3

Safety Monitoring

• Blood pressure weekly during medication transition [@clinical practice@]
• Weight weekly for 8 weeks [@clinical practice@]
• Liver function tests at baseline and 3 months (daridorexant, venlafaxine) 11
• Suicide risk assessment at each visit - antidepressants carry black box warning, though risk lower in elderly 4, 9